Patents by Inventor Qingping Zeng

Qingping Zeng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTIPLE KINASE PATHWAY INHIBITORS
    Publication number: 20150266870
    Abstract: Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.
    Type: Application
    Filed: September 25, 2013
    Publication date: September 24, 2015
    Inventors: Qingping Zeng, Mary Faris, Alexis Mollard, Steven L. Warner, Gary A. Flynn
  • IRE-1? inhibitors
    Patent number: 9040714
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts there-of. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: May 26, 2015
    Assignee: MannKind Corporation
    Inventors: Qingping Zeng, Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
  • IRE-1alpha INHIBITORS
    Publication number: 20150141424
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 21, 2015
    Inventors: Qingping ZENG, Andras TORO, John Bruce PATTERSON, Warren Stanfield WADE, Zoltan ZUBOVICS, Yun YANG, Zhipeng WU
  • IRE-1alpha INHIBITORS
    Publication number: 20140080832
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Application
    Filed: November 13, 2013
    Publication date: March 20, 2014
    Applicant: MANNKIND CORPORATION
    Inventors: John Bruce PATTERSON, David Gregory LONERGAN, Gary A. FLYNN, Qingping ZENG, Peter V. PALLAI
  • IRE-1? inhibitors
    Patent number: 8614253
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: December 24, 2013
    Assignee: MannKind Corporation
    Inventors: John Bruce Patterson, David Gregory Lonergan, Gary A. Flynn, Qingping Zeng, Peter V. Pallai
  • IRE-1alpha INHIBITORS
    Publication number: 20130116247
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts there-of. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Application
    Filed: April 5, 2011
    Publication date: May 9, 2013
    Applicant: MANNKIND CORPORATION
    Inventors: Qingping Zeng, Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
  • IRE-1alpha INHIBITORS
    Publication number: 20120270877
    Abstract: The invention provides compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Application
    Filed: November 1, 2010
    Publication date: October 25, 2012
    Applicant: MannKind Corporation
    Inventors: Qingping Zeng, Warren S. Wade, John Bruce Patterson
  • Thiazole compounds and methods of use
    Patent number: 8084479
    Abstract: The invention relates to methods of using thiazole compounds of Formula I and Formula II and compositions thereof for treating diseases mediated by protein kinase B (PKB) such as cancer and other proliferative disorders where the variables have the definitions provided herein.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: December 27, 2011
    Assignee: Amgen Inc.
    Inventors: Qingping Zeng, John G. Allen, Matthew P. Bourbeau, Celia Dominguez, Christopher H. Fotsch, Nianhe Han, Fang-Tsao Hong, Xin Huang, Matthew R. Lee, Aiwen Li, Qingyian Liu, James T. Rider, Seifu Tadesse, Andrew S. Tasker, Vellarkad N. Viswanadhan, Xianghong Wang, Kurt E. Weiler, George E. Wohlhieter, Guomin Yao, Chester Chenguang Yuan
  • FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE
    Publication number: 20110263647
    Abstract: The invention relates to thiazole compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Application
    Filed: January 13, 2010
    Publication date: October 27, 2011
    Applicant: AMGEN INC.
    Inventors: Qingping Zeng, Chester Chenguang Yuan, Guomin Yao, Xianghong Wang, Seifu Tadesse, David J. ST. Jean, JR., Andreas Reichelt, Qingyian Liu, Fang-Tsao Hong, Nianhe Han, Christopher H. Fotsch, Carl D. Davis, Matthew P. Bourbeau, Kate S. Ashton, John G. Allen
  • Thiadiazole modulators of PKB
    Patent number: 7919504
    Abstract: The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Grant
    Filed: July 15, 2008
    Date of Patent: April 5, 2011
    Assignee: Amgen Inc.
    Inventors: Qingping Zeng, Chester Chenguang Yuan, Guomin Yao, Xianghong Wang, Seifu Tadesse, Andreas Reichelt, Qingyian Liu, Matthew R. Lee, Xin Huang, Fang-Tsao Hong, Nianhe Han, Christopher H. Fotsch, Celia Dominguez, Matthew P. Bourbeau, John G. Allen
  • Thiadiazole compounds and methods of use
    Patent number: 7919514
    Abstract: The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Grant
    Filed: March 19, 2008
    Date of Patent: April 5, 2011
    Assignee: Amgen Inc.
    Inventors: Holger Monenschein, James Thomas Rider, Guomin Yao, Qingping Zeng
  • IRE-1alpha INHIBITORS
    Publication number: 20110065162
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Application
    Filed: November 8, 2010
    Publication date: March 17, 2011
    Applicant: MANNKIND CORPORATION
    Inventors: JOHN B. PATTERSON, DAVID G. LONERGAN, GARY A. FLYNN, QINGPING ZENG, PETER V. PALLAI
  • Heterocyclic modulators of PKB
    Patent number: 7897619
    Abstract: The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Grant
    Filed: July 16, 2008
    Date of Patent: March 1, 2011
    Assignee: Amgen Inc.
    Inventors: Qingping Zeng, Dawei Zhang, Guomin Yao, George E. Wohlhieter, Xianghong Wang, James Rider, Andreas Reichelt, Holger Monenschein, Fang-Tsao Hong, James R. Falsey, Celia Dominguez, Matthew P. Bourbeau, John G. Allen
  • IRE-1? inhibitors
    Patent number: 7858666
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: December 28, 2010
    Assignee: MannKind Corporation
    Inventors: John B. Patterson, David G. Lonergan, Gary A. Flynn, Qingping Zeng, Peter V. Pallai
  • Thiadiazole compounds and methods of use
    Patent number: 7700636
    Abstract: The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Grant
    Filed: March 19, 2008
    Date of Patent: April 20, 2010
    Assignee: Amgen Inc.
    Inventors: Holger Monenschein, George Erich Wohlhieter, Qingping Zeng
  • Thiadiazole modulators of PKB
    Publication number: 20090298836
    Abstract: The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Application
    Filed: July 15, 2008
    Publication date: December 3, 2009
    Applicant: Amgen Inc.
    Inventors: Qingping Zeng, Chester Chenguang Yuan, Guomin Yao, Xianghong Wang, Seifu Tadesse, Andreas Reichelt, Qingyian Liu, Matthew R. Lee, Xin Huang, Fang-Tsao Hong, Nianhe Han, Christopher H. Fotsch, Celia Dominguez, Matthew P. Bourbeau, John G. Allen
  • Heterocyclic modulators of PKB
    Publication number: 20090275592
    Abstract: The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Application
    Filed: July 16, 2008
    Publication date: November 5, 2009
    Applicant: Amgen Inc.
    Inventors: Qingping ZENG, Dawei ZHANG, Guomin YAO, George E. WOHLHIETER, Xianghong WANG, James RIDER, Andreas REICHELT, Holger MONENSCHEIN, Fang-Tsao HONG, James R. FALSEY, Celia DOMINGUEZ, Matthew P. BOURBEAU, John G. ALLEN
  • Thiazole compounds and methods of use
    Publication number: 20090270445
    Abstract: The invention relates to methods of using thiazole compounds of Formula I and Formula II and compositions thereof for treating diseases mediated by protein kinase B (PKB) such as cancer and other proliferative disorders where the variables have the definitions provided herein.
    Type: Application
    Filed: February 11, 2009
    Publication date: October 29, 2009
    Applicant: Amgen Inc.
    Inventors: Qingping Zeng, John G. Allen, Matthew P. Bourbeau, Celia Dominguez, Christopher H. Fotsch, Nianhe Han, Fang-Tsao Hong, Xin Huang, Matthew R. Lee, Aiwen Li, Qingyian Liu, James T. Rider, Seifu Tadesse, Andrew S. Tasker, Vellarkad N. Viswanadhan, Xianghong Wang, Kurt E. Weiler, George E. Wohlhieter, Guomin Yao, Chester Chenguang Yuan
  • IRE-1alpha INHIBITORS
    Publication number: 20090186893
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Application
    Filed: June 9, 2008
    Publication date: July 23, 2009
    Applicant: MANNKIND CORPORATION
    Inventors: John B. PATTERSON, David G. LONERGAN, Gary A. FLYNN, Qingping ZENG, Peter V. PALLAI
  • Thiazole compounds and methods of use
    Patent number: 7514566
    Abstract: The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: April 7, 2009
    Assignee: Amgen, Inc.
    Inventors: Qingping Zeng, John G. Allen, Matthew P. Bourbeau, Celia Dominguez, Christopher H. Fotsch, Nianhe Han, Fang-Tsao Hong, Xin Huang, Matthew R. Lee, Aiwen Li, Qingyian Liu, James T. Rider, Seifu Tadesse, Andrew S. Tasker, Vellarkad N. Viswanadhan, Xianghong Wang, Kurt E. Weiler, George E. Wohlhieter, Guomin Yao, Chester Chenguang Yuan